Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (191)
  2. Journal Article (123)
  3. Review (21)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (351)
  2. Center for Hematologic Malignancies (351)
  3. Department of Medicine (351)
  4. Hematologic Malignancies, Division of (351)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (15)
  2. 2024 (35)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (148)
  2. Journal of Clinical Oncology (18)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (164)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (22)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Meeting Abstract

    Smith, C. C.; Vachhani, P.; Garcia-Manero, G.; Grieselhuber, N. R.; Guru Murthy, G. S.; Bhatia, A.; Arora, J.; Izadi, H.; Fiorino, A.; Rampal, R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M. J.; Rampal, R.; Bose, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J. M.; Gerds, A. T.; Kiladjian, J. J.; Derkach, A.; Rampal, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study
    Meeting Abstract

    Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Treating accelerated and blast phase myeloproliferative neoplasms: Progress and challenges
    Review

    Ajufo, H. O.; Waksal, J. A.; Mascarenhas, J. O.; Rampal, R. K.
    Therapeutic Advances in Hematology (2023)

    Fulltext@MSK | Save
  • Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy
    Review

    Pemmaraju, N.; Bose, P.; Rampal, R.; Gerds, A. T.; Fleischman, A.; Verstovsek, S.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
    Journal Article

    Dunbar, A. J.; Kim, D.; Lu, M.; Farina, M.; Bowman, R. L.; Yang, J. L.; Park, Y.; Karzai, A.; Xiao, W.; Zaroogian, Z.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
    Journal Article

    Pemmaraju, N.; Kantarjian, H.; Sweet, K.; Wang, E.; Senapati, J.; Wilson, N. R.; Konopleva, M.; Frankel, A. E.; Gupta, V.; Mesa, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Ocular findings in patients with histiocytosis
    Meeting Abstract

    Francis, J. H.; Reiner, A. S.; Canestraro, J.; Raajit, R.; Abramson, D. H.; Diamond, E. L.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save